Elicio Therapeutics (NASDAQ:ELTX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Elicio Therapeutics (NASDAQ:ELTX) from a hold rating to a sell rating in a report issued on Saturday.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Friday, April 24th. LADENBURG THALM/SH SH initiated coverage on shares of Elicio Therapeutics in a research note on Wednesday, April 15th. They issued a “buy” rating and a $20.00 price objective for the company. HC Wainwright lifted their price objective on shares of Elicio Therapeutics from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Rodman & Renshaw upgraded shares of Elicio Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Elicio Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Elicio Therapeutics Trading Down 2.5%

NASDAQ:ELTX opened at $10.63 on Friday. The company has a current ratio of 2.24, a quick ratio of 2.38 and a debt-to-equity ratio of 5.75. The stock has a market capitalization of $202.93 million, a PE ratio of -4.43 and a beta of 1.12. The firm’s 50 day moving average is $11.22 and its 200 day moving average is $9.57. Elicio Therapeutics has a 12 month low of $5.15 and a 12 month high of $14.93.

Elicio Therapeutics (NASDAQ:ELTX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). Sell-side analysts expect that Elicio Therapeutics will post -1.7 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Elicio Therapeutics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock valued at $5,184,000 after buying an additional 19,240 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Elicio Therapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock valued at $1,055,000 after purchasing an additional 2,832 shares in the last quarter. 683 Capital Management LLC purchased a new position in shares of Elicio Therapeutics during the 4th quarter valued at $449,000. CIBC Bancorp USA Inc. purchased a new position in shares of Elicio Therapeutics during the 3rd quarter valued at $350,000. Finally, Cresset Asset Management LLC purchased a new position in shares of Elicio Therapeutics during the 3rd quarter valued at $295,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.